Skip to main content

Developing Therapeutic Antibodies for Pets

Project description

Therapeutic antibodies for dogs

Pet ownership in the EU is on the rise, and the global pet health market is worth more than EUR 10 billion. Current therapies for chronic inflammatory diseases, including inflammatory bowel disease, are costly and ineffective, often resulting in animal euthanasia. The EU-funded CAESAR project provides support to German biotech Adivo with the goal to develop therapeutic antibodies for dogs for treatment of cancer and chronic inflammation, with the potential of expansion into development of therapeutics for other species in the future. The company has already developed the first-of-a-kind synthetic canine phage-display library that would allow to generate therapeutic antibodies for dogs, with the first goal being to synthesise native specific therapeutic antibodies for the treatment of inflammatory bowel disease.

Field of science

  • /social sciences/economics and business/business and management/commerce
  • /medical and health sciences/health sciences/inflammatory diseases
  • /agricultural sciences/animal and dairy science/pets
  • /agricultural sciences/veterinary science
  • /medical and health sciences/clinical medicine/gastroenterology/inflammatory bowel disease

Call for proposal

H2020-SMEInst-2018-2020-1
See other projects for this call

Funding Scheme

SME-1 - SME instrument phase 1

Coordinator

ADIVO GMBH
Address
Am Klopferspitz 19
82152 Planegg
Germany
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 50 000